Norwell, Inc. Report issue

For profit Phase 2
Founded: Houston TX United States (2006)
Status: Defunct (2017)

Organization Overview

First Clinical Trial
2007
NCT00524277
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (4)

ae37 + gm-csf vaccine (1 trial)

gm-csf vaccine (1 trial)

gp2 peptide (1 trial)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 4